Company Analysis
Sign in

Cardiol Therapeutics Inc. (CRDL)

Nasdaq: CRDL · Biological Products, (No Diagnostic Substances) · Oakville, ON · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.3
◀ Past 6.1● Present 3.6▶ Future 6.4
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2021, as filed
RevenueC$78,760
Net income-C$31.6M-53.3%
Earnings per shareC$-0.73-5.8%
Operating cash flow-C$23.5M-157.8%
CashC$83.9M+498.2%
Debtn/a
Shareholders’ equityC$76.2M+474.5%
Shares, diluted43.2M+44.8%
Return on equity-189.2%
The recordfrom its filings
Filings in 202640
Newest filingNov 12 · 6-K
Annual reportMar 31, 2026
Quarterly reportn/a
Next report due40-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in CAD. Nothing here is a forecast.

News

Nov 3, 2026 · SEC EDGAR · Form SUPPL
Form SUPPL
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form SUPPL
Form SUPPL
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CRDL · research, not advice